Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...
The company added that details of the settlement are confidential. In March 2024, a jury found that Dexcom’s G6 glucose monitors infringed one of three of Abbott’s patents, but jurors couldn’t reach a ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...
Shares of DexCom Inc. DXCM rose 2.30% to $86.32 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and the ...
In March 2024, a jury found that Dexcom’s G6 glucose monitors infringed one of three of Abbott’s patents, but jurors couldn’t reach a verdict on a fourth patent.